UK - MSIF provides blood testing technology company with £100,000 investment

Merseyside Special Investment Fund has backed PalindromX, a blood testing technology company, with £100,000 of seed funding through its Liverpool Seed Fund. PalindromX is a spinout from the University of Liverpool. It has developed a patented technology that increases the sensitivity of blood testing. The technology gives a quicker and more accurate diagnosis that enables a more appropriate and timely treatment. It also significantly reduces costs by allowing doctors to run tests for several different substances simultaneously.